MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

Kodu・Aktsiate loetelu・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Suletud

SektorTervishoid

37.58 -0.71

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

37.14

Max

37.79

Põhinäitajad
By Trading Economics
Sissetulek	11M 51M
Müük	39M 239M
P/E Sektori keskmine	12.259 78.892
Aktsiakasum	1.08
Kasumimarginaal	21.242
Töötajad	268
EBITDA	14M 73M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+15.01% upside

Turustatistika
By TradingEconomics
Turukapital	551M 2.2B
Eelmine avamishind	38.29
Eelmine sulgemishind	37.58

Uudiste sentiment

By Acuity

50%

151 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

29.8 / N/A Toetus ja vastupanu

Harmony Biosciences Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

30. dets 2025, 23:49 UTC

Omandamised, ülevõtmised, äriostud

WiseTech to Sell Expedient to Appease Competition Regulator

30. dets 2025, 17:12 UTC

Suurimad hinnamuutused turgudel

CapsoVision Shares Rise on FDA Application for AI Tool in Swallowable Camera

30. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

30. dets 2025, 21:16 UTC

Omandamised, ülevõtmised, äriostud

Penguin Solutions: Smart Modular to Sell Zilia Stake for $46M

30. dets 2025, 21:08 UTC

Market Talk

U.S. Natural Gas Futures Take Another Wild Ride -- Market Talk

30. dets 2025, 20:41 UTC

Market Talk

Oil Futures Settle Lower in Sluggish Trade -- Market Talk

30. dets 2025, 20:37 UTC

Tulu

The 5 Best Names to Play AI in 2026, According to Wall Street's Loudest Tech Bull -- Barrons.com

30. dets 2025, 19:29 UTC

Market Talk

Corn Extends Pullback in Light Trade -- Market Talk

30. dets 2025, 18:29 UTC

Market Talk

U.S. Oil Rig Count Rises By Three to 412 -- Market Talk

30. dets 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

30. dets 2025, 16:20 UTC

Tulu

Boeing Stock Is on a Roll. Why It Could Gain 25% in the Next Year. -- Barrons.com

30. dets 2025, 16:18 UTC

Omandamised, ülevõtmised, äriostud

Meta Buys AI Startup Manus, Adding Millions of Paying Users -- 2nd Update

30. dets 2025, 16:10 UTC

Market Talk

Eurozone Government Bond Yields Rise, Euro Falls Ahead of Fed Minutes -- Market Talk

30. dets 2025, 15:24 UTC

Market Talk

Australian Dollar Could Rise Versus Sterling -- Market Talk

30. dets 2025, 15:10 UTC

Omandamised, ülevõtmised, äriostud

Meta Stock Rises After Buying Manus. What the China-Founded AI Start-Up Brings. -- Barrons.com

30. dets 2025, 14:24 UTC

Omandamised, ülevõtmised, äriostud

LVMH: The Three Publications Are Challenges, Sciences & Avenir, and La Recherche

30. dets 2025, 14:22 UTC

Omandamised, ülevõtmised, äriostud

LVMH : Szafran Will Serve as Publishing Director For all Three Publications

30. dets 2025, 14:20 UTC

Omandamised, ülevõtmised, äriostud

LVMH: As Part of the Deal, Maurice Szafran Has Been Named President of Les Editions Croque Futur

30. dets 2025, 14:17 UTC

Omandamised, ülevõtmised, äriostud

LVMH: The Deal Also Reflects LVMH's Commitment to Support High-Quality Information and Scientific Culture

30. dets 2025, 14:16 UTC

Omandamised, ülevõtmised, äriostud

LVMH: The Deal Aims to Accelerate the Development and Distribution of the Publications Mainly in Digital Format

30. dets 2025, 14:14 UTC

Omandamised, ülevõtmised, äriostud

LVMH: The Move Includes Three Publications Into UFIPAR Investment Company

30. dets 2025, 14:12 UTC

Omandamised, ülevõtmised, äriostud

LVMH: Les Editions Croque Futur Is a French Publishing House

30. dets 2025, 14:10 UTC

Omandamised, ülevõtmised, äriostud

LVMH Acquires Les Editions Croque Futur

30. dets 2025, 13:49 UTC

Omandamised, ülevõtmised, äriostud

Meta Buys Manus. What the China-Founded AI Start-Up Brings for Zuckerberg. -- Barrons.com

30. dets 2025, 13:36 UTC

Market Talk

U.S. Natural Gas Continues Weather-Driven Rally -- Market Talk

30. dets 2025, 13:30 UTC

Market Talk

Crude Futures Gain in Light Holiday Trade -- Market Talk

30. dets 2025, 12:55 UTC

Market Talk

Triple Flag Precious Metals Offers Opportunity While Mitigating Risk -- Market Talk

30. dets 2025, 11:55 UTC

Market Talk

Tulu

Investors Await Tesco's Profit Outlook Following U.K. Budget Reforms -- Market Talk

30. dets 2025, 11:47 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Meta's Manus Deal Is a Taster of AI Trends for 2026. Watch This Risk. -- Barrons.com

30. dets 2025, 11:35 UTC

Omandamised, ülevõtmised, äriostud

Meta Buys Manus. What the China-Founded AI Start-Up Brings for Zuckerberg. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Harmony Biosciences Holdings Inc Prognoos

Hinnasiht

By TipRanks

15.01% tõus

12 kuu keskmine prognoos

Keskmine 43.6 USD 15.01%

Kõrge 55 USD

Madal 32 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Harmony Biosciences Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Harmony Biosciences Holdings Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

29.8 / N/AToetus ja vastupanu

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

151 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.